Slide 1: Clinical Program Update AURORA 2 / voclosporin
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin December 9, 2021
Slide 2: AURORA 2 Readout Results
AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy AURORA 2 Readout Results
Slide 3: AURORA 2 Study Design
AURORA 2 Study Design AURORA 1 (n=357) One-Year Study AURORA 2 (n=216) Two-Year Study • AURORA 2 is a Phase 3, global, double-blind, two-year continuation study of AURORA 1 evaluating voclosporin compared to placebo, in combination with MMF and low-dose steroids, in subjects with lupus nephritis • T
Slide 4: AURORA 2 Demographics
Placebo n=% (n=100) Voclosporin n=% (n=116) Age, years Mean (SD) 11.64 (35.4) 10.31 (32.3) Sex, n (%) Female 88.0 (88) 90.5 (105) Male 12.0 (12) 9.5 (11) Race, n (%) White 40.0 (40) 37.9 (44) Asian 30.0 (30) 25.9 (30) Black 7.0 (7) 15.5 (18) Other 23.0 (23) 20.7 (24) Biopsy class, n (%) Pure Class I
Slide 5: AURORA 2 Clinical Characteristics
Placebo n=% (n=100) Voclosporin n=% (n=116) Corrected* eGFR, mL/min/1.73 m2, mean (SD) AURORA 1 Baseline 16.58 (78.7) 15.05 (79.0) AURORA 2 Baseline (Month 12) 12.61 (83.3) 13.53 (80.7) UPCR, mg/mg, mean (SD) AURORA 1 Baseline 2.4764 (3.868) 2.5766 (3.941) AURORA 2 Baseline (Month 12) 1.640 (1.47) 1
Slide 6: eGFR (Mean) Over Time
Corrected eGFR (mL/min/1.73m², mean) Over Time Baseline Month 3 Month 6 Month 9 Month 12 Month 15 Month 18 Month 21 Month 24 Month 27 Month 30 Month 33 Month 36 60 70 80 90 100 eG FR (m L/ m in /1 .7 3m ²) eGFR (Mean) Over Time AURORA 01 AURORA 02 4-week follow up 100 100 100 100 100 98 96 90 81 84
Slide 7: Mean UPCR (LSMean) by Visit
Mean UPCR by visit Baseline Month 3 Month 6 Month 9 Month 12 Month 15 Month 18 Month 21 Month 24 Month 27 Month 30 Month 33 Month 36 FUP 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 U PC R (m g/ m g) Mean UPCR (LSMean) (mg/mg) by Visit 100 100 100 100 100 96 96 90 81 86 87 84 87 85 116 111 116 116 116 113 113 10
Slide 8: Summary of AURORA 2 Adverse Events
Summary of AURORA 2 Adverse Events (AEs) Placebo (N = 100) Voclosporin (N = 116) % (n) % (n) Any AE 83.0 (83) 88.8 (103) Treatment-Related AE 25.0 (25) 27.6 (32) Serious AE 24.0 (24) 19.0 (22) Treatment-Related Serious AE 2.0 (2) 0.9 (1) AE Leading to voclosporin/Placebo Discontinuation 18.0 (18) 10
Slide 9: AURORA 2 Readout Results
AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy AURORA 2 Readout Results
Slide 10: Thank you
Thank you Trademarks are the property of Aurinia Pharmaceuticals Inc. © 2021 Aurinia Pharmaceuticals Inc. All rights reserved.